SEC Tracker
Get the app
ABVC · XBRL financial data

ABVC BioPharma financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ABVC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue162*11173892*——796———
Cost of revenue30139*0000*——————
Gross profit(14)(137)*11173892*——796———
Research and development14172*69403832*29333029*3323
Selling, general and administrative1,1821,527*831640301488*615690798784*752504
Total operating expenses2,1411,825*3,4451,094339336*6932,2951,9642,199*1,572780
Operating income (loss)(2,155)(1,962)*(3,444)(977)50(334)*(693)(2,295)(1,964)(2,199)*(1,572)(780)
Interest income4037*4274412*19194782*41
Interest expense1,2191,103*685260220(338)*2231293133*4942
Other income (expense)(1,214)1,248*30221789*2(7)2(10)*(1)7
Income tax expense (benefit)(1)175*—(111)00*—2410*——
Net income (loss)(3,318)(3,111)*(3,933)(942)(187)229*(842)(2,257)(2,042)(2,767)*(1,560)(737)
Earnings per share, basic USD per share(0.82)—(0.40)(0.09)(0.02)—(0.06)(0.13)(0.09)(0.11)*(0.06)(0.03)
Earnings per share, diluted USD per share(0.82)—(0.40)(0.09)(0.02)—(0.06)(0.13)(0.09)(0.11)*(0.06)(0.03)
Weighted average shares, basic thousands of shares4,055—9,73611,32112,40513,208*14,96817,38723,25724,683*25,44926,059
Weighted average shares, diluted thousands of shares4,055—9,73611,32112,40513,208*14,96817,38723,25724,683*25,44926,059

Balance sheet

CSV

Fiscal quarters (ABVC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents500603012413724815238819268114032
Short-term investments697976767165656565646262
Accounts receivable22222———————
Inventory——————111111———
Prepaid and other current assets143101160101919696195447347250152
Total current assets2,4941,6571,7942,1902,1482,1801,4702,7703,3122,501649412
Property and equipment, net7,9547,9697,9497,9297,9315118,1698,21512,85412,83512,82312,832
Right-of-use asset9008097086075086405334593691,9131,8271,744
Total assets16,59214,49314,46014,63414,4637,54014,87616,24121,21421,06219,73319,401
Accrued liabilities3,5583,696——————————
Total current liabilities5,3635,9326,6346,5496,3166,5576,7316,5336,5436,1645,3935,695
Lease liability, non-current5074073182291422371671771641,6011,5111,405
Total liabilities7,5306,3626,9736,8056,4846,8166,9196,7516,7197,7656,9047,131
Accumulated deficit(62,309)(65,420)(69,353)(70,366)(70,552)(68,950)(69,792)(72,049)(74,091)(76,858)(78,419)(79,156)
Total stockholders' equity9,1008,3887,7928,2938,3581,2265,4047,01412,06011,11210,77310,287
Total liabilities and equity16,59214,49314,46014,63414,4637,54014,87616,24121,21421,06219,73319,401
Common shares outstanding (cover page) thousands of shares7,23210,56010,85212,42212,97515,77816,77323,54224,30125,44026,00026,654

Cash flows

CSV

Fiscal quarters (ABVC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(3,318)(3,111)*(3,933)(942)(187)229*(842)(2,257)(2,042)(2,767)*(1,560)(737)
Stock-based compensation818226*2,54541396(184)*491,5721,1361,386*787253
Depreciation and amortization7———————————
Net cash from operating activities(1,359)*(479)*(473)(1,014)*172*(494)*(540)(894)*(965)*(588)*(894)(244)*
Purchases of property and equipment—0*——————————
Net cash from investing activities(74)*154*——45*———(513)*(30)*47(102)*
Proceeds from issuing common stock—0*——————————
Net cash from financing activities1,657*87*676869*(145)*581*4291,927*1,204*1,078*(342)226*
Net change in cash379*(404)*(58)84*27*94*(104)317*(222)*473*(1,187)(108)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Abvc Biopharma32not reported(244)*26.7M0.4 quarters 10-QJun 30, 2026
Karyopharm Therapeutics54,98033,432(24,931)*22.7M2.6 quarters 10-QJun 30, 2026
BriaCell Therapeutics9,852not reported(5,959)*8.7M3.4 quarters 10-KJul 31, 2026
Annovis Bio18,7290*(21,914)*42.6M0.9 quarters 10-QJun 30, 2026
Atara Biotherapeutics3,221630(3,338)*10.0M3.0 quarters 10-QJun 30, 2026
Grace Therapeutics13,756not reported(3,221)21.0M4.3 quarters 10-QJun 30, 2026
CervoMed22,4630(6,918)*15.1M3.6 quarters 10-QJun 30, 2026
Kezar Life Sciences66,229not reported(7,445)7.4M8.9 quarters 10-QMar 31, 2026
Actuate Therapeutics4,426not reported(4,405)*24.0M1.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.